128 related articles for article (PubMed ID: 24807674)
1. Downregulation of galectin-3 causes a decrease in uPAR levels and inhibits the proliferation, migration and invasion of hepatocellular carcinoma cells.
Zheng D; Hu Z; He F; Gao C; Xu L; Zou H; Wu Z; Jiang X; Wang J
Oncol Rep; 2014 Jul; 32(1):411-8. PubMed ID: 24807674
[TBL] [Abstract][Full Text] [Related]
2. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
[TBL] [Abstract][Full Text] [Related]
3. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
4. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
5. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Notch1 inhibits the invasion of human hepatocellular carcinoma HepG2 and MHCC97H cells through the regulation of PTEN and FAK.
Hu YJ; Li HY; Qiu KJ; Li DC; Zhou JH; Hu YH; Zhang FM
Int J Mol Med; 2014 Oct; 34(4):1081-6. PubMed ID: 25110169
[TBL] [Abstract][Full Text] [Related]
7. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
8. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
9. EFEMP1 inhibits migration of hepatocellular carcinoma by regulating MMP2 and MMP9 via ERK1/2 activity.
Dou CY; Cao CJ; Wang Z; Zhang RH; Huang LL; Lian JY; Xie WL; Wang LT
Oncol Rep; 2016 Jun; 35(6):3489-95. PubMed ID: 27108677
[TBL] [Abstract][Full Text] [Related]
10. MECP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in human hepatocellular carcinoma HEPG2 cells.
Zhao LY; Zhang J; Guo B; Yang J; Han J; Zhao XG; Wang XF; Liu LY; Li ZF; Song TS; Huang C
Cell Mol Biol (Noisy-le-grand); 2013 Nov; Suppl 59():OL1876-81. PubMed ID: 24199952
[TBL] [Abstract][Full Text] [Related]
11. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
Liao YJ; Fang CC; Yen CH; Hsu SM; Wang CK; Huang SF; Liang YC; Lin YY; Chu YT; Arthur Chen YM
Int J Cancer; 2015 Sep; 137(6):1341-51. PubMed ID: 25754535
[TBL] [Abstract][Full Text] [Related]
12. miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway.
Gu W; Li X; Wang J
Oncol Rep; 2014 Jan; 31(1):397-404. PubMed ID: 24190507
[TBL] [Abstract][Full Text] [Related]
13. Sirt6 suppresses hepatocellular carcinoma cell growth via inhibiting the extracellular signal‑regulated kinase signaling pathway.
Zhang ZG; Qin CY
Mol Med Rep; 2014 Mar; 9(3):882-8. PubMed ID: 24366394
[TBL] [Abstract][Full Text] [Related]
14. Tissue factor pathway inhibitor-2 silencing promotes hepatocellular carcinoma cell invasion in vitro.
Zhu B; Zhang P; Zeng P; Huang Z; Dong TF; Gui YK; Zhang GW
Anat Rec (Hoboken); 2013 Nov; 296(11):1708-16. PubMed ID: 24591127
[TBL] [Abstract][Full Text] [Related]
15. PBK overexpression promotes metastasis of hepatocellular carcinoma via activating ETV4-uPAR signaling pathway.
Yang QX; Zhong S; He L; Jia XJ; Tang H; Cheng ST; Ren JH; Yu HB; Zhou L; Zhou HZ; Ren F; Hu ZW; Gong R; Huang AL; Chen J
Cancer Lett; 2019 Jun; 452():90-102. PubMed ID: 30914208
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Nowicki TS; Zhao H; Darzynkiewicz Z; Moscatello A; Shin E; Schantz S; Tiwari RK; Geliebter J
Cell Cycle; 2011 Jan; 10(1):100-7. PubMed ID: 21191179
[TBL] [Abstract][Full Text] [Related]
17. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
18. Urokinase induces stromal cell-derived factor-1 expression in human hepatocellular carcinoma cells.
Hsu WH; Chen CN; Huang HI; Lai YL; Teng CY; Kuo WH
J Cell Physiol; 2012 Feb; 227(2):697-704. PubMed ID: 21465475
[TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
Bessard A; Frémin C; Ezan F; Fautrel A; Gailhouste L; Baffet G
Oncogene; 2008 Sep; 27(40):5315-25. PubMed ID: 18521085
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
